Insurance refusals keep GLP-1 drugs out of reach for many hormone disorder patients
Women with polyendocrine metabolic ovarian syndrome often cannot obtain GLP-1 medications because insurers deem the use off-label and refuse to cover the high cost.
Polyendocrine metabolic ovarian syndrome patients are turning to GLP-1 medications for better blood-sugar regulation, weight management and fertility, but most insurers label the prescription off-label and deny reimbursement, forcing patients to pay hundreds to thousands of dollars. Jez Roberts, 39, and nurse Bethany Hughes describe being unable to afford the treatment, while Emma Ranta in Portland secured a $50-a-month plan after her insurer approved it.
Endocrinologists Mihail Zilbermint and Mark Fendrick note that insulin resistance makes GLP-1s clinically valuable, yet fragmented payer decisions and cost worries stall wider coverage. Policy adviser Katherine Hempstead calls the situation an equity issue, and Fendrick outlines three routes to lower prices: government intervention, higher volume prescribing, or cutting other health-care expenditures. Medicare’s recently launched GLP-1 Bridge Program offers a $50 monthly option for qualifying patients, potentially setting a precedent for broader insurance adoption.
Why it matters
Without insurance coverage, many PMOS patients lack access to an effective, affordable therapy, deepening health disparities.
In this story